Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience

Detalhes bibliográficos
Autor(a) principal: Silva, Wellington Fernandes da
Data de Publicação: 2020
Outros Autores: Rosa, Lidiane Inês da, Seguro, Fernanda Salles, Silveira, Douglas Rafaele Almeida, Bendit, Israel, Buccheri, Valeria, Velloso, Elvira Deolinda Rodrigues Pereira, Rocha, Vanderson, Rego, Eduardo M.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Clinics
Texto Completo: https://www.revistas.usp.br/clinics/article/view/168740
Resumo: OBJECTIVES: The outcomes of refractory and relapsed acute myeloid leukemia (AML) patients in developing countries are underreported, even though the similar classic regimens are widely used. METHODS: We conducted a retrospective comparison of ‘‘MEC’’ (mitoxantrone, etoposide, and cytarabine) and ‘‘FLAG-IDA’’ (fludarabine, cytarabine, idarubicin, and filgrastim) in adults with first relapse or refractory AML. RESULTS: In total, 60 patients were included, of which 28 patients received MEC and 32 received FLAG-IDA. A complete response (CR) rate of 48.3% was observed. Of the included patients, 16 (27%) died before undergoing bone marrow assessment. No statiscally significant difference in CR rate was found between the two protocols (p=0.447). The median survival in the total cohort was 4 months, with a 3-year overall survival (OS) rate of 9.7%. In a multivariable model including age, fms-like tyrosine kinase 3 (FLT3) status, and stem-cell transplantation (SCT), only the last two indicators remained significant: FLT3-ITD mutation (hazard ratio [HR] =4.6, po0.001) and SCT (HR=0.43, p=0.01). CONCLUSION: In our analysis, there were no significant differences between the chosen regimens. High rates of early toxicity were found, emphasizing the role of supportive care and judicious selection of patients who are eligible for intensive salvage therapy in this setting. The FLT3-ITD mutation and SCT remained significant factors for survival in our study, in line with the results of previous studies.
id USP-19_a346d3384184b8969231c6f59ee9633a
oai_identifier_str oai:revistas.usp.br:article/168740
network_acronym_str USP-19
network_name_str Clinics
repository_id_str
spelling Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experienceAcute Myeloid LeukemiaSalvage RegimensPrognostic FactorsSurvivalCohort StudyOBJECTIVES: The outcomes of refractory and relapsed acute myeloid leukemia (AML) patients in developing countries are underreported, even though the similar classic regimens are widely used. METHODS: We conducted a retrospective comparison of ‘‘MEC’’ (mitoxantrone, etoposide, and cytarabine) and ‘‘FLAG-IDA’’ (fludarabine, cytarabine, idarubicin, and filgrastim) in adults with first relapse or refractory AML. RESULTS: In total, 60 patients were included, of which 28 patients received MEC and 32 received FLAG-IDA. A complete response (CR) rate of 48.3% was observed. Of the included patients, 16 (27%) died before undergoing bone marrow assessment. No statiscally significant difference in CR rate was found between the two protocols (p=0.447). The median survival in the total cohort was 4 months, with a 3-year overall survival (OS) rate of 9.7%. In a multivariable model including age, fms-like tyrosine kinase 3 (FLT3) status, and stem-cell transplantation (SCT), only the last two indicators remained significant: FLT3-ITD mutation (hazard ratio [HR] =4.6, po0.001) and SCT (HR=0.43, p=0.01). CONCLUSION: In our analysis, there were no significant differences between the chosen regimens. High rates of early toxicity were found, emphasizing the role of supportive care and judicious selection of patients who are eligible for intensive salvage therapy in this setting. The FLT3-ITD mutation and SCT remained significant factors for survival in our study, in line with the results of previous studies.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2020-04-13info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/xmlhttps://www.revistas.usp.br/clinics/article/view/16874010.6061/clinics/2020/e1566Clinics; Vol. 75 (2020); e1566Clinics; v. 75 (2020); e1566Clinics; Vol. 75 (2020); e15661980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/168740/160226https://www.revistas.usp.br/clinics/article/view/168740/160227Copyright (c) 2020 Clinicsinfo:eu-repo/semantics/openAccessSilva, Wellington Fernandes daRosa, Lidiane Inês daSeguro, Fernanda SallesSilveira, Douglas Rafaele AlmeidaBendit, IsraelBuccheri, ValeriaVelloso, Elvira Deolinda Rodrigues PereiraRocha, VandersonRego, Eduardo M.2020-04-13T19:50:02Zoai:revistas.usp.br:article/168740Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2020-04-13T19:50:02Clinics - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience
title Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience
spellingShingle Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience
Silva, Wellington Fernandes da
Acute Myeloid Leukemia
Salvage Regimens
Prognostic Factors
Survival
Cohort Study
title_short Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience
title_full Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience
title_fullStr Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience
title_full_unstemmed Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience
title_sort Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience
author Silva, Wellington Fernandes da
author_facet Silva, Wellington Fernandes da
Rosa, Lidiane Inês da
Seguro, Fernanda Salles
Silveira, Douglas Rafaele Almeida
Bendit, Israel
Buccheri, Valeria
Velloso, Elvira Deolinda Rodrigues Pereira
Rocha, Vanderson
Rego, Eduardo M.
author_role author
author2 Rosa, Lidiane Inês da
Seguro, Fernanda Salles
Silveira, Douglas Rafaele Almeida
Bendit, Israel
Buccheri, Valeria
Velloso, Elvira Deolinda Rodrigues Pereira
Rocha, Vanderson
Rego, Eduardo M.
author2_role author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Silva, Wellington Fernandes da
Rosa, Lidiane Inês da
Seguro, Fernanda Salles
Silveira, Douglas Rafaele Almeida
Bendit, Israel
Buccheri, Valeria
Velloso, Elvira Deolinda Rodrigues Pereira
Rocha, Vanderson
Rego, Eduardo M.
dc.subject.por.fl_str_mv Acute Myeloid Leukemia
Salvage Regimens
Prognostic Factors
Survival
Cohort Study
topic Acute Myeloid Leukemia
Salvage Regimens
Prognostic Factors
Survival
Cohort Study
description OBJECTIVES: The outcomes of refractory and relapsed acute myeloid leukemia (AML) patients in developing countries are underreported, even though the similar classic regimens are widely used. METHODS: We conducted a retrospective comparison of ‘‘MEC’’ (mitoxantrone, etoposide, and cytarabine) and ‘‘FLAG-IDA’’ (fludarabine, cytarabine, idarubicin, and filgrastim) in adults with first relapse or refractory AML. RESULTS: In total, 60 patients were included, of which 28 patients received MEC and 32 received FLAG-IDA. A complete response (CR) rate of 48.3% was observed. Of the included patients, 16 (27%) died before undergoing bone marrow assessment. No statiscally significant difference in CR rate was found between the two protocols (p=0.447). The median survival in the total cohort was 4 months, with a 3-year overall survival (OS) rate of 9.7%. In a multivariable model including age, fms-like tyrosine kinase 3 (FLT3) status, and stem-cell transplantation (SCT), only the last two indicators remained significant: FLT3-ITD mutation (hazard ratio [HR] =4.6, po0.001) and SCT (HR=0.43, p=0.01). CONCLUSION: In our analysis, there were no significant differences between the chosen regimens. High rates of early toxicity were found, emphasizing the role of supportive care and judicious selection of patients who are eligible for intensive salvage therapy in this setting. The FLT3-ITD mutation and SCT remained significant factors for survival in our study, in line with the results of previous studies.
publishDate 2020
dc.date.none.fl_str_mv 2020-04-13
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/clinics/article/view/168740
10.6061/clinics/2020/e1566
url https://www.revistas.usp.br/clinics/article/view/168740
identifier_str_mv 10.6061/clinics/2020/e1566
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/clinics/article/view/168740/160226
https://www.revistas.usp.br/clinics/article/view/168740/160227
dc.rights.driver.fl_str_mv Copyright (c) 2020 Clinics
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2020 Clinics
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/xml
dc.publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
dc.source.none.fl_str_mv Clinics; Vol. 75 (2020); e1566
Clinics; v. 75 (2020); e1566
Clinics; Vol. 75 (2020); e1566
1980-5322
1807-5932
reponame:Clinics
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Clinics
collection Clinics
repository.name.fl_str_mv Clinics - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||clinics@hc.fm.usp.br
_version_ 1800222764738543616